AZN.UK

10,174

+0.06%↑

GSK

1,398.5

+0.25%↑

AZN.UK

10,174

+0.06%↑

GSK

1,398.5

+0.25%↑

AZN.UK

10,174

+0.06%↑

GSK

1,398.5

+0.25%↑

AZN.UK

10,174

+0.06%↑

GSK

1,398.5

+0.25%↑

AZN.UK

10,174

+0.06%↑

GSK

1,398.5

+0.25%↑

Search

Indivior PLC

Atvērts

981.5 -3.01

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

971

Max

1014

Galvenie mērījumi

By Trading Economics

Ienākumi

-19M

47M

Pārdošana

-33M

266M

P/E

Sektora vidējais

330

50.291

EPS

0.41

Peļņas marža

17.669

Darbinieki

1,030

EBITDA

-30M

76M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+1.66% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 24. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

504M

1.3B

Iepriekšējā atvēršanas cena

984.51

Iepriekšējā slēgšanas cena

981.5

Indivior PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 26. jūn. 23:49 UTC

Peļņas

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

2025. g. 26. jūn. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

2025. g. 26. jūn. 21:30 UTC

Peļņas

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

2025. g. 26. jūn. 21:07 UTC

Peļņas

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

2025. g. 26. jūn. 23:49 UTC

Tirgus saruna

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

2025. g. 26. jūn. 23:39 UTC

Tirgus saruna

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

2025. g. 26. jūn. 23:34 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

2025. g. 26. jūn. 23:33 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

2025. g. 26. jūn. 23:32 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers Will No Longer Receive Earnings From BWP Management

2025. g. 26. jūn. 23:32 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

2025. g. 26. jūn. 23:31 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

2025. g. 26. jūn. 23:31 UTC

Iegādes, apvienošanās, pārņemšana

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

2025. g. 26. jūn. 23:30 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

2025. g. 26. jūn. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

2025. g. 26. jūn. 23:19 UTC

Iegādes, apvienošanās, pārņemšana

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

2025. g. 26. jūn. 22:06 UTC

Peļņas

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025. g. 26. jūn. 21:15 UTC

Peļņas

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

2025. g. 26. jūn. 21:07 UTC

Iegādes, apvienošanās, pārņemšana

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

2025. g. 26. jūn. 21:07 UTC

Iegādes, apvienošanās, pārņemšana

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

2025. g. 26. jūn. 21:07 UTC

Iegādes, apvienošanās, pārņemšana

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

2025. g. 26. jūn. 21:07 UTC

Peļņas

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025. g. 26. jūn. 21:06 UTC

Iegādes, apvienošanās, pārņemšana

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

2025. g. 26. jūn. 21:06 UTC

Iegādes, apvienošanās, pārņemšana

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

2025. g. 26. jūn. 21:06 UTC

Tirgus saruna

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

2025. g. 26. jūn. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025. g. 26. jūn. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025. g. 26. jūn. 20:52 UTC

Peļņas

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

2025. g. 26. jūn. 20:51 UTC

Peļņas

Correct: Nike 4Q Net $211M, Not $200M >NKE

2025. g. 26. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 26. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Indivior PLC Prognoze

Cenas mērķis

By TipRanks

1.66% augšup

Prognoze 12 mēnešiem

Vidējais 1,024.7 GBX  1.66%

Augstākais 1,100 GBX

Zemākais 949.403 GBX

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Indivior PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

3

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.